BusinessVaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)By Nasdaq OMXOct 26, 2017, 2:23 PM UTC
BusinessProtein Expression Market to Reach $3 billion by 2023: P&S Market ResearchBy Nasdaq OMXSep 14, 2017, 5:30 AM UTC
BusinessVaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung CancerBy Nasdaq OMXOct 6, 2016, 1:45 PM UTC
